Full-Time
AI-driven healthcare data analysis platform
$90k - $150k/yr
Mid
Company Historically Provides H1B Sponsorship
Los Angeles, CA, USA
Role is based in Los Angeles, CA.
Get referrals →
You have ways to get a Tempus referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 13 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data to assist physicians in making informed treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Additionally, Tempus conducts research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Relocation Assistance
Company Equity
Performance Bonus
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes.
NewEdge Advisors LLC invests $49,000 in Tempus AI, Inc. (NASDAQ:TEM).
Valued at a market cap today of $9.2 billion, Tempus AI stock has surged around 47% since its initial public offering in June 2024.
Tempus AI has entered into strategic partnerships with AstraZeneca and Pathos AI to develop a multimodal foundation model in oncology.
Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs.